实验室2024年获科研项目5项，包括国家自然科学基金面上项目2项，湖南省自然科学基金项目2项，横向课题1项，总经费121.5万元；发表第一/通讯作者论文19篇，其中影响因子大于10的 SCI论文2篇，包括Nucleic Acids Research（IF:14.9）和Cell Death and Differentiation（IF: 13.7）各1篇；具体如下：

（一）承担课题

1.国家自然科学基金委员会，面上项目，82470176，急性髓系白血病中MCL-1/BAK相互作用调控凋亡的分子机制及其小分子抑制剂开发，2025/01-2028/12, 48.5万元，危蝴蝶主持。

2. 国家自然科学基金委员会，面上项目，82474131, 紫草素靶向SIRT1驱动代谢重编程逆转前列腺癌恩杂鲁胺耐药的作用机制研究, 2025-01-01 至 2028-12-31, 48万元，张叶主持。

3. 湖南省自然科学基金委员会，面上项目，2024JJ5567，紫草素促进OPN泛素化抑制肝癌增殖转移的机制研究，2024-01-01 至 2026-12-31，5万元，张叶主持。

4. 湖南省自然科学基金联合基金项目，2024JJ9131，运用单细胞蛋白质组学技术筛选肺腺癌脑转移循环肿瘤细胞的早期诊断标志物，2024/01-2026/12，5万元，张鹏飞主持

5.湖南省地质院地球化学过程与资源环境效应湖南省重点实验室，横向课题，GRE202304K，湖南省典型镉污染土壤及其农作物的生物毒理效应分析研究，2024/6-2025/6，15万元，张鹏飞主持

（二）发表论文

1. Shuyan Dai^#, Liang Guo^#, Raja Dey^#, Ming Guo, Xiangqian Zhang, Darren Bates, Justin Cayford, Longying Jiang, Hudie Wei, Zhuchu Chen, Ye Zhang*, Lin Chen*, Yongheng Chen*. Structural insights into the HDAC4–MEF2A–DNA complex and its implication in long-range transcriptional regulation. Nucleic Acids Research, 2024, 52(5):2711-2723. (IF: 14.9，JCR1区)

2. Deng Y, Lu L, Zhu D, Zhang H, Fu Y, Tan Y, Tan X, Guo M, Zhang Y, Yang H, Yang B, Liu T, Chen Y. MafG/MYH9-LCN2 axis promotes liver fibrosis through inhibiting ferroptosis of hepatic stellate cells. Cell Death Differ. 2024 Sep;31(9):1127-1139. (IF:13.7, JCR1区)

3.Guyu Tang, Jing Liu, Xiaomei Gao, Wei Tang, Jiaxian Chen, Menghai Wu, Zhengtong Lv, Ye Zhang*, Yi Cai*, Lin Qi*. circWSB1 promotes tumor progression in ccRCC via circWSB1/miR-182-5p/WSB1 axis. International Journal of Biological Macromolecules, 2024, 256: 128338-128350. (IF: 8.2，JCR1区)

4. Xinying Zhang(#), Ziyue Yang, Chunmeng Fu, Run Yao, Huan Li, Fang Peng*, Ning Li*. Emerging roles of liquid-liquid phase saration in liver innate immunity. Cell Commun Signal. 2024 Sep 3;22(1):430. （IF：8.2，JCR1区）

5. Li Y, Zhang X, Liu N, Liu R, Zhang W, Chen L, Chen Y. RNF166 promotes colorectal cancer progression by recognizing and destabilizing poly-ADP-ribosylated angiomotins. Cell Death Dis. 2024 Mar 13;15(3):211. (IF:8.1, JCR1区)

6. Jingzhi Li, Ming Guo, Lin Chen, Zhuchu Chen, Ying Fu(*), Yongheng Chen(*). Amyloid aggregates induced by the p53-R280T mutation lead to loss of p53 function in nasopharyngeal carcinoma. Cell Death & Disease. 2024;15(1):35. （IF:8.1, JCR1区）

7. Yang F, Lin Q, Song X, Huang H, Chen X, Tan J, Li Y, Zhou Y, Tu Z, Du H, Zhang ZM, Ortega R, Lin X, Patterson AV, Smaill JB, Chen Y, Lu X. Discovery of 6-Formylpyridyl Urea Derivatives as Potent Reversible-Covalent Fibroblast Growth Factor Receptor 4 Inhibitors with Improved Anti-Hepatocellular Carcinoma Activity. J Med Chem. 2024 Feb 22;67(4):2667-2689. (IF:6.79, JCR1区)

8.Xiaojuan Chen, Huiliang Li, Qianmeng Lin, Shuyan Dai, Lingzhi Qu, Ming Guo, Lin Zhang, Jiaxuan Liao, Hudie Wei, Guangyu Xu *, Longying Jiang *, Yongheng Chen *. Design, synthesis, and biological evaluation of selective covalent inhibitors of FGFR4, European Journal of Medicinal Chemistry. 2024 Mar 15:268:116281. (IF:6.0, JCR1区)

9.Wuqing Deng#, Xiaojuan Chen#, Hong Liang, Xiaojuan Song, Shuang Xiang, Jing Guo, Zhengchao Tu, Yang Zhou *, Yongheng Chen *, Xiaoyun Lu *. Design, synthesis and biological evaluation of 5-amino-1H-pyrazole-4-carboxamide derivatives as pan-FGFR covalent inhibitors, European Journal of Medicinal Chemistry. 2024 Sep 5:275:116558. (IF:6.0, JCR1区)

10.Qianmeng Lin, Shuyan Dai, Lingzhi Qu, Hang Lin, Ming Guo, Hudie Wei, Yongheng Chen *, Xiaojuan Chen *. Structural basis and selectivity of sulfatinib binding to FGFR and CSF-1R, Communications Chemistry. 2024 Jan 3;7(1):3. (IF:5.9, JCR1区)

11. Xiuzhi Zhang(#), Zhefeng Xiao(#), Xia Zhang, Ningning Li, Tao Sun, JinZhong Zhang, Chunyan Kang, Shasha Fan(*), Liping Dai(*), Xiaoli Liu(*)，Signature construction and molecular subtype identification based on liver-specific genes for prediction of prognosis, immune activity, and anti-cancer drug sensitivity in hepatocellular carcinoma，Cancer Cell International, 2024.02.19; 24(1):78. (IF:5.3, JCR1区)

12. Xuan Zheng(#), Zhiwen Chen(#), Ming Guo(#), Hong Liang, Xiaojuan Song, Yiling Liu, Zhenling Liao,Yan Zhang, Jing Guo, Yang Zhou, Zhi-min Zhang, Zhengchao Tu, Ye Zhang, Yongheng Chen(*),Zhang Zhang(*), and Xiaoyun Lu(*), Structure-Based Optimization of Pyrazinamide-Containing Macrocyclic Derivatives as Fms-like Tyrosine Kinase 3 (FLT3) Inhibitors to Overcome Clinical Mutations, ACS Pharmacology & Translational Science, 2024, 7, 5, 1485–1506 (IF:5.1, JCR1区)

13. Zhe Cheng, Huichao Huang 2, Maoyu Li(*), Yongheng Chen(*)；Proteomic analysis identifies PFKP lactylation in SW480 colon cancer cells；iScience 27, 108645, January 19, 2024（IF:4.6, JCR2区）

14. Xia X, Lin Q, Zhou Z, Chen Y. An imbalanced GLP-1R/GIPR co-agonist peptide

with a site-specific N-terminal PEGylation to maximize metabolic benefits. iScience. 2024 Mar 1;27(4):109377. （IF:4.6, JCR2区）

15. Jiang L, Liu X, Liang X, Dai S, Wei H, Guo M, Chen Z, Xiao D, Chen Y. Structural characterization of the DNA binding mechanism of retinoic acid-related orphan receptor gamma. Structure. 2024 Apr 4;32(4):467-475. (IF:4.39, JCR1区)

16. Qi Zhang; Jixiang Zhou; Denggao Zhai; Qin Jiang; Manyi Yang; Maojun Zhou*, Gut microbiota regulates the ALK5/NOX1 axis by altering glutamine metabolism to inhibit ferroptosis of intrahepatic cholangiocarcinoma cells, Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2024，1870（5），167152. ( IF:4.19, JCR1区)

17. Liang, X., Guo, M., Jiang, L., Fu, Y., Zhang, P., & Chen, Y. (2024). Predicting miRNA-Disease Associations by Combining Graph and Hypergraph Convolutional Network. Interdisciplinary sciences, computational life sciences. (IF:3.9, JCR1区)

18.Liu Shilei(#); Li Xiaoxiao(#); Xie Qingming; Zhang Sai; Liang Xujun;  Li Shisheng;  Zhang Pengfei(*). Identification of a lncRNA/circRNA- miRNA-mRNA

network in Nasopharyngeal Carcinoma by deep sequencing and bioinformatics analysis.  J Cancer. 2024 Feb 11;15(7):1916-1928. （IF:3.3, JCR2区）

19.Xie Qingming; Liu Shilei; Zhang Sai; Liao Liqiu; Xiao Zhi; Wang Shouman; Zhang Pengfei(*). Clin Exp Med. 2024 Mar 1;24(1):49. （IF:3.2, JCR2区）